Aim: To evaluate the outcome and toxicities of stereotactic ablative radiotherapy (SABR) for skeletal metastasis in a tertiary cancer center.
INTRODUCTION
Management of metastatic diseases has been evolving rapidly over the past few years with the advancement in systemic treatment, radiotherapy technique and diagnostic imaging. The theory of oligometastases, which is introduced by Hellman et al., 1 defined an intermediate stage of malignancy between localized disease and widespread metastases. Paradigms of management of oligometastases (OM) have also been shifting from purely palliative systemic treatment to potentially curative intervention by metastasectomy over the past two decades. [2] [3] [4] Growing evidences suggested that metastasectomy, either by surgical resection or local ablative treatment (LAT), may delay progression if not for complete cure for selected patients with OM. 5 Oligoprogression (OP), on the other hand, represents another condition which refers to the development of limited progressive sites while systemic treatment is still able to control majority of tumor.
Eradication of these resistant subclones may allow continuation of systemic treatment and delay systemic progression. 6 Oligometastatic skeletal metastases (OM-SM) or oligoprogresive skeletal metastases (OP-SM) are not uncommon in clinical practice.
Up to 40% of cancer patients will indeed develop spinal metastases. 7 Although SM, unlike other visceral metastases, is generally not life threatening, they can cause significant morbidities including pathological fracture or spinal cord compression. Conventional palliative is unsatisfactory and the duration of pain control is limited with a median of 3-6 months. 8 Re-irradiation by conventional technique is sometimes feasible but dose and efficacy is often limited. On the contrary, stereotactic ablative radiotherapy (SABR), which allows precise delivery of high dose radiation in a few fractions, is a novel effective LAT in management of SM. 9 With its merits of being a non-invasive LAT, its application has been expanding in treatment of SM. [10] [11] [12] Herein, we are going to report our institutional experience of utilization of SABR in OM-SM or OP-SM. 
TA B L E 1 Patients characteristics (n =
22
METHODS AND MATERIALS

RESULTS
From October 2012 to March 2017, there are total of 27 SABR treatments in 22 patients, with 15 females and seven males. The median age of this series is 64 years. Primary cancers include non-small cell lung cancer (NSCLC; 50%) and breast cancer (32%), followed by nasopharyngeal cancer (9%), colon cancer, (4.5%) and prostate cancer (4.5%).
One patient has synchronous NSCLC & clinical pancreatic cancer.
There are 12 patients with OM and 10 patients with OP. Eighteen patients (82%) received SABR for only one treatment site. Twentyone patients (95.4%) have further systemic treatment after SABR. The details are shown in Table 1 .
There are 20 spinal metastases and seven non-spinal metastases. As Vertebroplasty at L3 is performed due to persistent mechanical pain.
One patient is suffering from grade 3 esophagitis after SABR to T5 
DISCUSSION
The current study reports the clinical outcome of SABR to SM in our institution. This study is in echo with previous different case series of good LC of SABR to either spine or non-spinal metastases. has also been demonstrated in SABR to non-spinal metastases by different retrospective series but in general, the number of patients in these studies is less than those in spinal metastases. 10, 16 In our studies, out of the three LFs, two of them are having relatively large GTVs (55.1 cm 3 for L4 and L5 vertebrae and 55.5 cm 3 for left ilium). Indeed, there are limited evidences on the dosimetric or clinical parameters which may affect the LC of SABR for SM. In general, GTV volume is not a selection criterion for skeletal SABR among different studies, and under-dosing is often related to the distance between the GTV to the critical neurological structures like spinal cord or cauda equina rather than the GTV size. The effect of tumor size on LC is more evident in SABR of primary lung cancer. 17 However, it is obvious that a large GTV size may more be associated with tumor hypoxia which may have an adverse outcome on the LC. Further studies are essentially needed to clarify this issue. compression fracture and these data exclude those with local progression. Sahgal et al. 19 also observed the 1-and 2-year cumulative incidences of fracture were 12.4% and 13.5%. Our rate of vertebral fracture is similar to other series yet the number is small to make any conclusion in this aspect.
Although SABR to SM in general achieves excellent LC, most patients developed distant progression eventually at some time point.
OM diseases are a subset of metastatic disease which the tumor biological behavior may be different from those widespread metastases.
In our cohort, the median PFS of the OM disease is 10.6 months, which suggests a relatively stable disease control after SABR. Interest- and survival data are also heavily influenced by the further systemic treatment received rather than the pure effect of SABR.
In conclusion, our series demonstrated SABR to SM achieves good LC with acceptable toxicities. However, prospective data on pain control and survival in OM and OP diseases are still eagerly awaited in the future. Being a safe and non-invasive LAT, the role of SABR in treatment of OP or OP SM will certainly be evolving in the future.
